Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Advanced Cancers
Interventions
DRUG

Lenalidomide

Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.

DRUG

Bevacizumab

Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.

DRUG

Sorafenib

Starting dose: 200 mg by mouth daily for 28 a day cycle.

DRUG

Temsirolimus

Starting dose: 15 mg by vein every week for a 28 day cycle.

DRUG

Lenalidomide

Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.

DRUG

Oxaliplatin

Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.

DRUG

Leucovorin

400 mg/m2 by vein on day 1 of a 21 day cycle.

DRUG

5-fluorouracil

400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER